Cyclo Therapeutics, Inc. (CYTH)
USD 0.72
(0.0%)
USD 0.72
(0.0%)
| Year | Revenue | Revenue Growth |
|---|---|---|
| 2023 | 1.07 Million USD | -21.76% |
| 2022 | 1.37 Million USD | -13.24% |
| 2021 | 1.58 Million USD | 75.54% |
| 2020 | 903.37 Thousand USD | -10.31% |
| 2019 | 1 Million USD | -0.42% |
| 2018 | 1.01 Million USD | -18.28% |
| 2017 | 1.23 Million USD | -17.64% |
| 2016 | 1.5 Million USD | 58.13% |
| 2015 | 950.45 Thousand USD | -39.36% |
| 2014 | 1.56 Million USD | -7.43% |
| 2013 | 1.69 Million USD | 62.05% |
| 2012 | 1.04 Million USD | 1.27% |
| 2011 | 1.03 Million USD | 28.6% |
| 2010 | 802.37 Thousand USD | 28.61% |
| 2009 | 623.87 Thousand USD | 26.05% |
| 2008 | 494.93 Thousand USD | -34.11% |
| 2007 | 751.17 Thousand USD | 38.51% |
| 2006 | 542.31 Thousand USD | 19.36% |
| 2005 | 454.36 Thousand USD | -2.22% |
| 2004 | 464.69 Thousand USD | 17.78% |
| 2003 | 394.53 Thousand USD | -24.47% |
| 2002 | 522.37 Thousand USD | 80.49% |
| 2001 | 289.42 Thousand USD | -24.74% |
| 2000 | 384.59 Thousand USD | 0.0% |
| Year | Revenue | Revenue Growth |
|---|---|---|
| 2024 Q2 | 123.1 Thousand USD | -39.19% |
| 2024 Q1 | 202.45 Thousand USD | -34.99% |
| 2023 FY | 1.07 Million USD | -21.76% |
| 2023 Q1 | 152.41 Thousand USD | -18.41% |
| 2023 Q2 | 117.11 Thousand USD | -23.16% |
| 2023 Q4 | 311.39 Thousand USD | -37.15% |
| 2023 Q3 | 495.47 Thousand USD | 323.06% |
| 2022 Q1 | 194.9 Thousand USD | -66.69% |
| 2022 FY | 1.37 Million USD | -13.24% |
| 2022 Q4 | 186.8 Thousand USD | -58.69% |
| 2022 Q3 | 452.16 Thousand USD | -16.56% |
| 2022 Q2 | 541.88 Thousand USD | 178.03% |
| 2021 Q3 | 403.91 Thousand USD | 69.29% |
| 2021 Q2 | 238.59 Thousand USD | -33.38% |
| 2021 FY | 1.58 Million USD | 75.54% |
| 2021 Q1 | 358.13 Thousand USD | 145.99% |
| 2021 Q4 | 585.11 Thousand USD | 44.86% |
| 2020 Q2 | 209.59 Thousand USD | -35.65% |
| 2020 FY | 903.37 Thousand USD | -10.31% |
| 2020 Q3 | 222.46 Thousand USD | 6.14% |
| 2020 Q4 | 145.58 Thousand USD | -34.56% |
| 2020 Q1 | 325.73 Thousand USD | 43.27% |
| 2019 Q1 | 220.82 Thousand USD | -7.8% |
| 2019 Q3 | 285.91 Thousand USD | 4.69% |
| 2019 Q4 | 227.36 Thousand USD | -20.48% |
| 2019 FY | 1 Million USD | -0.42% |
| 2019 Q2 | 273.09 Thousand USD | 23.67% |
| 2018 Q1 | 198.06 Thousand USD | 17.57% |
| 2018 Q3 | 224.48 Thousand USD | -35.76% |
| 2018 Q4 | 239.51 Thousand USD | 6.7% |
| 2018 FY | 1.01 Million USD | -18.28% |
| 2018 Q2 | 349.41 Thousand USD | 76.41% |
| 2017 Q2 | 523.08 Thousand USD | 71.47% |
| 2017 Q1 | 305.05 Thousand USD | -42.18% |
| 2017 Q4 | 168.46 Thousand USD | -30.14% |
| 2017 FY | 1.23 Million USD | -17.64% |
| 2017 Q3 | 241.14 Thousand USD | -53.9% |
| 2016 Q4 | 527.64 Thousand USD | 89.67% |
| 2016 Q1 | 312.68 Thousand USD | 92.71% |
| 2016 FY | 1.5 Million USD | 58.13% |
| 2016 Q2 | 384.38 Thousand USD | 22.93% |
| 2016 Q3 | 278.19 Thousand USD | -27.63% |
| 2015 Q2 | 380.34 Thousand USD | 119.6% |
| 2015 Q1 | 173.19 Thousand USD | -61.17% |
| 2015 Q4 | 162.25 Thousand USD | -30.85% |
| 2015 FY | 950.45 Thousand USD | -39.36% |
| 2015 Q3 | 234.66 Thousand USD | -38.3% |
| 2014 FY | 1.56 Million USD | -7.43% |
| 2014 Q1 | 560.32 Thousand USD | 139.22% |
| 2014 Q4 | 446.02 Thousand USD | 15.1% |
| 2014 Q3 | 387.5 Thousand USD | 123.23% |
| 2014 Q2 | 173.58 Thousand USD | -69.02% |
| 2013 Q3 | 167.28 Thousand USD | -76.38% |
| 2013 Q4 | 234.23 Thousand USD | 40.02% |
| 2013 Q2 | 708.32 Thousand USD | 21.39% |
| 2013 Q1 | 583.49 Thousand USD | 96.15% |
| 2013 FY | 1.69 Million USD | 62.05% |
| 2012 Q3 | 157.37 Thousand USD | 6.2% |
| 2012 Q4 | 297.46 Thousand USD | 89.02% |
| 2012 Q2 | 148.19 Thousand USD | -66.47% |
| 2012 Q1 | 441.9 Thousand USD | 149.81% |
| 2012 FY | 1.04 Million USD | 1.27% |
| 2011 FY | 1.03 Million USD | 28.6% |
| 2011 Q1 | 254.36 Thousand USD | -7.3% |
| 2011 Q2 | 369.34 Thousand USD | 45.2% |
| 2011 Q3 | 231.23 Thousand USD | -37.39% |
| 2011 Q4 | 176.9 Thousand USD | -23.5% |
| 2010 Q3 | 196.53 Thousand USD | 27.09% |
| 2010 Q1 | 169.52 Thousand USD | 3.62% |
| 2010 FY | 802.37 Thousand USD | 28.61% |
| 2010 Q2 | 154.64 Thousand USD | -8.78% |
| 2010 Q4 | 274.38 Thousand USD | 39.61% |
| 2009 Q3 | 215.33 Thousand USD | 73.03% |
| 2009 FY | 623.87 Thousand USD | 26.05% |
| 2009 Q1 | 120.49 Thousand USD | -2.6% |
| 2009 Q2 | 124.44 Thousand USD | 3.28% |
| 2009 Q4 | 163.59 Thousand USD | -24.03% |
| 2008 Q1 | 68.47 Thousand USD | -64.62% |
| 2008 Q4 | 123.7 Thousand USD | -12.95% |
| 2008 Q3 | 142.1 Thousand USD | -11.55% |
| 2008 Q2 | 160.65 Thousand USD | 134.64% |
| 2008 FY | 494.93 Thousand USD | -34.11% |
| 2007 Q3 | 226.71 Thousand USD | 26.16% |
| 2007 FY | 751.17 Thousand USD | 38.51% |
| 2007 Q4 | 193.54 Thousand USD | -14.63% |
| 2007 Q2 | 179.69 Thousand USD | 18.8% |
| 2007 Q1 | 151.26 Thousand USD | 11.98% |
| 2006 Q2 | 127.44 Thousand USD | -23.6% |
| 2006 FY | 542.31 Thousand USD | 19.36% |
| 2006 Q4 | 135.08 Thousand USD | 19.58% |
| 2006 Q3 | 112.97 Thousand USD | -11.36% |
| 2006 Q1 | 166.81 Thousand USD | 105.34% |
| 2005 FY | 454.36 Thousand USD | -2.22% |
| 2005 Q1 | 118.54 Thousand USD | 53.66% |
| 2005 Q2 | 135.65 Thousand USD | 14.44% |
| 2005 Q3 | 118.92 Thousand USD | -12.33% |
| 2005 Q4 | 81.23 Thousand USD | -31.69% |
| 2004 Q4 | 77.14 Thousand USD | -42.48% |
| 2004 FY | 464.69 Thousand USD | 17.78% |
| 2004 Q3 | 134.11 Thousand USD | 11.53% |
| 2004 Q2 | 120.25 Thousand USD | -9.71% |
| 2004 Q1 | 133.17 Thousand USD | -21.19% |
| 2003 Q1 | 50.54 Thousand USD | -14.06% |
| 2003 FY | 394.53 Thousand USD | -24.47% |
| 2003 Q4 | 168.98 Thousand USD | 97.61% |
| 2003 Q3 | 85.51 Thousand USD | -4.43% |
| 2003 Q2 | 89.48 Thousand USD | 77.03% |
| 2002 Q4 | 58.81 Thousand USD | -56.98% |
| 2002 Q2 | 130.99 Thousand USD | -33.11% |
| 2002 Q1 | 195.84 Thousand USD | 253.63% |
| 2002 Q3 | 136.71 Thousand USD | 4.36% |
| 2002 FY | 522.37 Thousand USD | 80.49% |
| 2001 Q2 | 84.81 Thousand USD | -7.99% |
| 2001 Q1 | 92.18 Thousand USD | 29.0% |
| 2001 FY | 289.42 Thousand USD | -24.74% |
| 2001 Q4 | 55.38 Thousand USD | -9.6% |
| 2001 Q3 | 61.26 Thousand USD | -27.77% |
| 2000 Q3 | 76.3 Thousand USD | 0.0% |
| 2000 FY | 384.59 Thousand USD | 0.0% |
| 2000 Q4 | 71.46 Thousand USD | -6.35% |
| Name | Revenue | Revenue Difference |
|---|---|---|
| ANI Pharmaceuticals, Inc. | 486.81 Million USD | 99.779% |
| Aquestive Therapeutics, Inc. | 50.58 Million USD | 97.872% |
| Collegium Pharmaceutical, Inc. | 566.76 Million USD | 99.81% |
| Cosmos Health Inc. | 53.37 Million USD | 97.983% |
| Esperion Therapeutics, Inc. | 116.33 Million USD | 99.075% |
| Cronos Group Inc. | 88.84 Million USD | 98.788% |
| Incannex Healthcare Limited | 12 Thousand USD | -8870.042% |
| Kala Pharmaceuticals, Inc. | - USD | -Infinity% |
| Lifecore Biomedical, Inc. | 128.26 Million USD | 99.161% |
| Regencell Bioscience Holdings Limited | - USD | -Infinity% |
| Sunshine Biopharma, Inc. | 24.09 Million USD | 95.532% |
| Sunshine Biopharma, Inc. | 24.09 Million USD | 95.532% |
| SCYNEXIS, Inc. | 140.14 Million USD | 99.232% |
| Safety Shot Inc | 202.67 Thousand USD | -431.112% |
| Theratechnologies Inc. | 81.76 Million USD | 98.684% |
| Alpha Teknova, Inc. | 36.68 Million USD | 97.066% |
| Universe Pharmaceuticals INC | 32.3 Million USD | 96.668% |
| Pacira BioSciences, Inc. | 674.97 Million USD | 99.841% |
| Sonoma Pharmaceuticals, Inc. | 12.73 Million USD | 91.548% |
| Dynavax Technologies Corporation | 232.28 Million USD | 99.537% |
| Ironwood Pharmaceuticals, Inc. | 442.73 Million USD | 99.757% |
| Radius Health, Inc. | 2.88 Billion USD | 99.963% |
| China SXT Pharmaceuticals, Inc. | 1.92 Million USD | 44.184% |
| Alvotech | 91.43 Million USD | 98.823% |
| Intra-Cellular Therapies, Inc. | 464.37 Million USD | 99.768% |
| SIGA Technologies, Inc. | 139.91 Million USD | 99.231% |
| Shineco, Inc. | 9.8 Million USD | 89.018% |
| Silver Spike Investment Corp. | 11.72 Million USD | 90.817% |
| Journey Medical Corporation | 79.18 Million USD | 98.641% |
| Petros Pharmaceuticals, Inc. | 5.82 Million USD | 81.513% |
| Embecta Corp. | 1.12 Billion USD | 99.904% |
| Harrow Health, Inc. | 130.19 Million USD | 99.173% |
| Procaps Group, S.A. | 409.92 Million USD | 99.737% |
| Biofrontera Inc. | 34.07 Million USD | 96.841% |
| DURECT Corporation | 8.54 Million USD | 87.408% |
| PainReform Ltd. | - USD | -Infinity% |
| Supernus Pharmaceuticals, Inc. | 607.52 Million USD | 99.823% |
| OptiNose, Inc. | 70.98 Million USD | 98.484% |
| RedHill Biopharma Ltd. | 6.51 Million USD | 83.473% |
| Organogenesis Holdings Inc. | 433.14 Million USD | 99.751% |
| Cumberland Pharmaceuticals Inc. | 39.55 Million USD | 97.279% |
| ProPhase Labs, Inc. | 44.38 Million USD | 97.575% |
| Phibro Animal Health Corporation | 1.01 Billion USD | 99.894% |
| Procaps Group S.A. | 409.92 Million USD | 99.737% |
| TherapeuticsMD, Inc. | 1.3 Million USD | 17.327% |
| Viatris Inc. | 15.42 Billion USD | 99.993% |
| Rockwell Medical, Inc. | 83.61 Million USD | 98.713% |
| Aytu BioPharma, Inc. | 81 Million USD | 98.671% |
| Tilray Brands, Inc. | 788.94 Million USD | 99.864% |
| PetIQ, Inc. | 1.1 Billion USD | 99.902% |
| Talphera, Inc. | 651 Thousand USD | -65.346% |
| Neurocrine Biosciences, Inc. | 1.88 Billion USD | 99.943% |
| Alimera Sciences, Inc. | 80.75 Million USD | 98.667% |
| Assertio Holdings, Inc. | 152.06 Million USD | 99.292% |
| Shuttle Pharmaceuticals Holdings, Inc. | - USD | -Infinity% |
| Avadel Pharmaceuticals plc | 27.96 Million USD | 96.151% |
| Hempacco Co., Inc. | 4.04 Million USD | 73.393% |
| Alvotech | 91.43 Million USD | 98.823% |
| Lantheus Holdings, Inc. | 1.29 Billion USD | 99.917% |
| Kamada Ltd. | 144.75 Million USD | 99.256% |
| Currenc Group, Inc. | 53.25 Million USD | 97.979% |
| Indivior PLC | 1.09 Billion USD | 99.902% |
| Evoke Pharma, Inc. | 5.18 Million USD | 79.223% |
| Flora Growth Corp. | 76.07 Million USD | 98.585% |
| Cyclo Therapeutics, Inc. | 1.07 Million USD | 0.0% |
| Evolus, Inc. | 202.08 Million USD | 99.467% |
| HUTCHMED (China) Limited | 837.99 Million USD | 99.872% |
| Amphastar Pharmaceuticals, Inc. | 644.39 Million USD | 99.833% |
| Akanda Corp. | 2.16 Million USD | 50.168% |